CrkRS is a Cdc2-related protein kinase that contains an arginine-and serine-rich (SR) domain, a characteristic of the SR protein family of splicing factors, and is proposed to be involved in RNA processing. However, whether it acts together with a cyclin and at which steps it may function to regulate RNA processing are not clear. Here, we report that CrkRS interacts with cyclin L1 and cyclin L2, and thus rename it as the long form of cyclin-dependent kinase 12 (CDK12 L ). A shorter isoform of CDK12, CDK12 S , that differs from CDK12 L only at the carboxyl end, was also identified. Both isoforms associate with cyclin L1 through interactions mediated by the kinase domain and the cyclin domain, suggesting a bona fide CDK/cyclin partnership. Furthermore, CDK12 isoforms alter the splicing pattern of an E1a minigene, and the effect is potentiated by the cyclin domain of cyclin L1. When expression of CDK12 isoforms is perturbed by small interfering RNAs, a reversal of the splicing choices is observed. The activity of CDK12 on splicing is counteracted by SF2/ASF and SC35, but not by SRp40, SRp55, and SRp75. Together, our findings indicate that CDK12 and cyclin L1/L2 are cyclin-dependent kinase and cyclin partners and regulate alternative splicing.It is estimated that fewer than 30,000 genes are present in the human genome (13). The heterogeneity generated by this number of genes is not enough to account for the complexity that specifies human organs. One way to create more proteomic variations is through alternative splicing (2, 21). About 38 to 74% of human genes are subject to alternative splicing (3,14,15), and mutations that affect splicing patterns are the underlying causes of some cancers and neurodegenerative diseases (10, 29). It is estimated that ϳ15% of disease-causing mutations in human genes involve misregulation of alternative splicing (25). Thus, unraveling the pathways and the molecules involved in alternative splicing is crucial to an understanding of various intricate cellular functions and for the management of human diseases.Although cyclin-dependent kinases (CDKs) and their associated cyclins are pivotal for cell cycle progression and RNA transcription (23), evidence has emerged that they also engage in the regulation of RNA splicing (19,27). For example, CDK11 p110 colocalizes with the general splicing factor RNPS1 (20) and serine-and arginine-rich (SR) proteins, such as 9G8 (12). Moreover, depletion of CDK11 p110 immune complex impedes the efficiency of an in vitro splicing assay (12). Similarly, blocking the activity of cyclin L1, a cyclin partner of CDK11 p110 , inhibits the second step (cutting of the lariat-exon intermediate and ligation of adjacent exons) of pre-mRNA splicing in an in vitro assay (7).A recently identified Cdc2-related kinase, CrkRS, is also implicated in the regulation of RNA splicing (16). CrkRS contains an arginine-and serine-rich (RS) domain, a characteristic found in the SR protein family of splicing factors. Furthermore, CrkRS localizes in nuclear speckles and CrkRS-immun...